Department of Biomedical Sciences, University of Sassari, Sassari, Italy.
Mult Scler. 2018 Jan;24(1):42-47. doi: 10.1177/1352458517737370.
Two human endogenous retroviruses of the HERV-W family are proposed as multiple sclerosis (MS) co-factors: MS-associated retrovirus (MSRV) and ERVWE1, whose env proteins showed several potentially neuropathogenic features, in vitro and in animal models. Phase II clinical trials against HERV-Wenv are ongoing. HERV-W/MSRV was repeatedly found in MS patients, in striking parallel with MS stages, active/remission phases, and therapy outcome. The HERV-Wenv protein is highly expressed in active MS plaques. Early MSRV presence in spinal fluids predicted worst MS progression 10 years in advance. Effective anti-MS therapies strongly reduced MSRV/Syncytin-1/HERV-W expression. The Epstein-Barr virus (EBV) activates HERV-W/MSRV in vitro and in vivo, in patients with infectious mononucleosis and controls with high anti-EBNA1-IgG titers. Thus, the two main EBV/MS links (infectious mononucleosis and high anti-EBNA1-IgG titers) are paralleled by activation of HERV-W/MSRV. It is hypothesized that EBV may act as initial trigger of future MS, years later, by activating MSRV, which would act as direct neuropathogenic effector, before and during MS.
两种人类内源性逆转录病毒家族 HERV-W 被认为是多发性硬化症(MS)的协同因子:与 MS 相关的逆转录病毒(MSRV)和 ERVWE1,其 env 蛋白在体外和动物模型中表现出多种潜在的神经致病性特征。针对 HERV-Wenv 的 II 期临床试验正在进行中。MSRV 在 MS 患者中反复被发现,与 MS 阶段、活动/缓解期和治疗结果非常相似。在活动期 MS 斑块中,HERV-W/env 蛋白高度表达。早期 MSRV 在脊髓液中的存在预测 10 年内 MS 进展最严重。有效的抗 MS 治疗强烈降低了 MSRV/Syncytin-1/HERV-W 的表达。EB 病毒(EBV)在体外和体内激活 HERV-W/MSRV,在传染性单核细胞增多症患者和高抗 EBVNA1-IgG 滴度的对照组中。因此,EBV 与 MS 的两个主要关联(传染性单核细胞增多症和高抗 EBVNA1-IgG 滴度)通过激活 HERV-W/MSRV 而平行存在。据推测,EBV 可能在数年后通过激活 MSRV 作为未来 MS 的初始触发因素,MSRV 在此之前和期间作为直接神经致病性效应物发挥作用。